PDCD1 and non-small cell lung carcinoma: Notably, although FAP expression was reported as an independent biomarker of a poor prognosis for lung adenocarcinoma (LUAD) (Moreno-Ruiz et al. 2021), none of the previous studies have confirmed the possibility that FAP is linked to the outcome of PD-1 blockade therapy and immune infiltrates in advanced NSCLC.